Last reviewed · How we verify
Injectable sodium deoxycholate
Injectable sodium deoxycholate, marketed by Goldman, Butterwick, Fitzpatrick and Groff, holds a unique position in its therapeutic class with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent, which helps maintain its competitive edge. The primary risk is the potential for increased competition following the patent expiry in 2028.
At a glance
| Generic name | Injectable sodium deoxycholate |
|---|---|
| Also known as | Kybella |
| Sponsor | Goldman, Butterwick, Fitzpatrick and Groff |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma (PHASE1)
- Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (PHASE2)
- Kybella With Triamcinolone (PHASE4)
- Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)
- A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal (NA)
- Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat (PHASE4)
- To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101 (PHASE1)
- Phase 2 Study for the Treatment of Superficial Lipomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: